[
    [
        {
            "time": "",
            "original_text": "上海新世纪资信评估维持复星医药(600196)主体及债项AAA信用等级，展望稳定。",
            "features": {
                "keywords": [
                    "复星医药",
                    "信用等级",
                    "AAA",
                    "展望稳定"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "上海新世纪资信评估维持复星医药(600196)主体及债项AAA信用等级，展望稳定。",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 6,
                "Headline_Structure": 5,
                "Source_Recency": 5
            }
        },
        {
            "time": "",
            "original_text": "2018年中国医药健康产业上市企业创新能力TOP100",
            "features": {
                "keywords": [
                    "2018年",
                    "医药健康",
                    "创新能力",
                    "TOP100"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "2018年中国医药健康产业上市企业创新能力TOP100",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 4,
                "Duration": 5,
                "Entity_Density": 4,
                "Market_Scope": 8,
                "Time_Proximity": 3,
                "Headline_Structure": 7,
                "Source_Recency": 2
            }
        },
        {
            "time": "",
            "original_text": "港股异动丨医药板块普跌 中生物制药跌逾4%",
            "features": {
                "keywords": [
                    "港股",
                    "医药板块",
                    "普跌",
                    "中生物制药",
                    "跌逾4%"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "港股异动丨医药板块普跌 中生物制药跌逾4%",
                "Correlation": 7,
                "Sentiment": 3,
                "Importance": 7,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 6,
                "Market_Scope": 8,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "2018年A股药企研发投入概况回顾",
            "features": {
                "keywords": [
                    "2018年",
                    "A股",
                    "药企",
                    "研发投入",
                    "回顾"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "2018年A股药企研发投入概况回顾",
                "Correlation": 5,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 4,
                "Duration": 5,
                "Entity_Density": 4,
                "Market_Scope": 8,
                "Time_Proximity": 3,
                "Headline_Structure": 6,
                "Source_Recency": 2
            }
        },
        {
            "time": "",
            "original_text": "医药板块估值重塑 性价比优势凸显 六股值得关注",
            "features": {
                "keywords": [
                    "医药板块",
                    "估值重塑",
                    "性价比",
                    "六股",
                    "关注"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药板块估值重塑 性价比优势凸显 六股值得关注",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 6
            }
        }
    ]
]